New cancer drugs help J&J top profit estimates

Updated: Tue, Oct 17, 2017
10:22 pm
Reuters
RELATED NEWS
Global Markets - Stocks rally on trade hopes, dollar set for first positive week of 2019 Global Markets - Stocks rally on trade hopes, dollar set for first positive week of 2019
Explainer - How pressing is Lebanon's financial challenge? Explainer - How pressing is Lebanon's financial challenge?
Lilly cancer drug fails key trial, will no longer be prescribed Lilly cancer drug fails key trial, will no longer be prescribed
Citi says female employees earn 29 percent less than men Citi says female employees earn 29 percent less than men
PBGC steps in to oversee Sears' two pension plans PBGC steps in to oversee Sears' two pension plans

Johnson & Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year.

Shares of J&J, part of the Dow Jones Industrial Average, rose 2.4 percent to $139.37 on Tuesday.

The shares have traded at or near record levels for much of the year. Guggenheim Securities analyst Tony Butler said the stock has historically done well when its high-margin pharmaceuticals business is the main driver of growth, rather than its consumer segment.

Sales at J&J`s pharmaceuticals segment rose 15.4 percent to $9.7 billion in the third quarter. Around half of that growth came from the Actelion deal.

Higher demand for J&J`s blood cancer drugs, Darzalex and Imbruvica, and Actelion`s rare diseases treatments are expected to boost earnings going forward.

The two cancer drugs should continue to capture market share, Guggenheim Securities` Butler said.

"The oncology business is doing exceptionally well," he said. "It`s really hard to figure out where that stops for both Darzalex and Imbruvica."

Still, sales of J&J`s diabetes drug, Invokana, slipped around 10 percent from the second quarter. The company this year was required to add new warnings about the risk of foot and leg amputations and also has had to contend with competition from Eli Lilly and Co`s Jardiance.

Its rheumatoid arthritis drug, Remicade, also had weaker sales in the quarter.

J&J said adjusted earnings, excluding one-time items, rose 13 percent to $1.90 per share. Analysts on average were expecting an adjusted profit of $1.80 per share , according to Thomson Reuters I/B/E/S.

Sales at J&J`s consumer products segment, which makes Band-Aids, Neutrogena beauty products and Tylenol, rose 2.9 percent to $3.4 billion.

The company`s net earnings fell to $3.76 billion, or $1.37 per share, in the quarter from $4.27 billion, or $1.53 per share, a year earlier. The company said it was hurt by amortization and deal-related expenses.

J&J raised its 2017 profit forecast to $7.25 to $7.30 per share, from its previous forecast of $7.12 to $7.22 per share. It now expects revenue of $76.1 billion to $76.5 billion for the year.

Johnson & Johnson has 6 drug manufacturing facilities on Puerto Rico, which was hit by Hurricane Maria last month. It said that while they are all running again, it cannot rule out intermittent shortages of some of its drugs.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link

Close